Evidence map›Paper›PMID 31088527›Full record

ArticleBMC cancer2019

Induction of tolerogenic dendritic cells by activated TGF-β/Akt/Smad2 signaling in RIG-I-deficient stemness-high human liver cancer cells.

Ming Zhong, Cheng Zhong, Wen Cui, Guanghui Wang, Gongpu Zheng, Li Li, Jing Zhang, Rujing Ren, Huijei Gao, Tingting Wang and 3 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 64 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Breaking Immunosuppression to Enhance Cancer Stem Cell-Targeted Immunotherapy.International journal of biological sciences · 2025
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Harnessing innate immune pathways for therapeutic advancement in cancer.Signal transduction and targeted therapy · 2024
    Review
  12. Unveiling the mechanisms and challenges of cancer drug resistance.Cell communication and signaling : CCS · 2024
    Review
  13. RNA mFrontiers in immunology · 2024
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Ming ZhongInstitute of Tumor Pharmacology, Jining Medical College, Xueyuan Road 669, Rizhao, 276826, China. zhongming0410@163.com.ORCID http://orcid.org/0000-0002-1869-2901
Cheng ZhongDivision of Stem Cell Dynamics, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Wen CuiInstitute of Tumor Pharmacology, Jining Medical College, Xueyuan Road 669, Rizhao, 276826, China. cuiwenmd@163.com.
Guanghui WangInstitute of Tumor Pharmacology, Jining Medical College, Xueyuan Road 669, Rizhao, 276826, China.
Gongpu ZhengInstitute of Tumor Pharmacology, Jining Medical College, Xueyuan Road 669, Rizhao, 276826, China.
Li LiInstitute of Tumor Pharmacology, Jining Medical College, Xueyuan Road 669, Rizhao, 276826, China.
Jing ZhangInstitute of Tumor Pharmacology, Jining Medical College, Xueyuan Road 669, Rizhao, 276826, China.
Rujing RenInstitute of Tumor Pharmacology, Jining Medical College, Xueyuan Road 669, Rizhao, 276826, China.
Huijei GaoInstitute of Tumor Pharmacology, Jining Medical College, Xueyuan Road 669, Rizhao, 276826, China.
Tingting WangPeople's Hospital of Rizhao, Rizhao, China.
Xin LiPeople's Hospital of Rizhao, Rizhao, China.
Jiantu CheS&V Biological Science and Technology Co., Ltd., Beijing, China.
Eiichi GohdaDivision of Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Jining Medical University · CNPeople’s Hospital of Rizhao · CNOkayama University · JPThe University of Tokyo · JP

Funding

Natural Science Foundation of Shandong Province ZR2014HM038
6 · The paper itself

Abstract

backgroundDendritic cells (DCs) alter their role from being immunostimulatory to immunosuppressive at advanced stages of tumor progression, but the influence of cancer stem cells (CSCs) and their secreted factors on generation and phenotypic change of DCs is unknown. Retinoic acid-inducible gene I (RIG-I) plays a role in regulation of other cellular processes including leukemic stemness besides its antiviral function.

methodsShort hairpin RNA-mediated gene silencing was employed to generate stable RIG-I-knocked-down human hepatocellular carcinoma (HCC) cell lines. Expression levels of genes and proteins in spheres of those HCC cells were determined by quantitative real-time PCR and Western bot, respectively. Levels of secreted cytokines were measured by ELISA. The surface molecule expression levels of DCs were analyzed using flow cytometry. The ability of DCs to induce proliferation of T cells was assessed by a mixed lymphocyte reaction (MLR) assay.

resultsRIG-I-knocked-down HCC cells showed upregulated expression of stem cell marker genes, enhanced secretion of factors suppressing in vitro generation of DCs into the conditioned medium (CM), and induction of a phenotype of tumor-infiltrating DCs (TIDCs) with low levels of DC markers in their tumors in nude mice. Those DCs and TIDCs showed reduced MLR, indicating RIG-I deficiency-induced immunotolerance. The RIG-I-deficient HCC cells secreted more TGF-β1 than did reference cells. The tumors formed after injection of RIG-I-deficient HCC cells had higher TGF-β1 contents than did tumors derived from control cells. DC generation and MLR suppressed by the CM of RIG-I-deficient HCC cells were restored by an anti-TGF-β1 antibody. TGF-β1-induced phosphorylation of Smad2 and Akt was enhanced in RIG-I-deficient HCC spheres, knockdown of AKT gene expression abolishing the augmentation of TGF-β1-induced Smad2 phosphorylation. Akt and p-Akt were co-immunoprecipitated with Smad2 in cytoplasmic proteins of RIG-I-deficient spheres but not in those of control spheres, the amounts of co-immunoprecipitated Akt and p-Akt being increased by TGF-β stimulation.

conclusionsOur results demonstrate that RIG-I deficiency in HCC cells induced their stemness, enhanced secretion and signaling of TGF-β1, tolerogenic TIDCs and less generation of DCs, and the results suggest involvement of TGF-β1 in those RIG-I deficiency-induced tolerogenic changes and involvement of CSCs in DC-mediated immunotolerance.

Indexed as

Signal TransductionAnimalsCarcinoma, HepatocellularCell Line, TumorCells, CulturedCoculture TechniquesDEAD Box Protein 58Dendritic CellsGene Expression Regulation, NeoplasticHumansLiver NeoplasmsMaleMiceNeoplasm TransplantationNeoplastic Stem CellsProto-Oncogene Proteins c-aktDEAD Box Protein 58Proto-Oncogene Proteins c-aktReceptors, ImmunologicRIGI protein, humanSmad2 ProteinSMAD2 protein, humanTGFB1 protein, humanTransforming Growth Factor beta1Hepatocellular carcinomaImmune toleranceMixed lymphocyte reactionTumor-infiltrating dendritic cellTumor microenvironment

Identifiers

PMID31088527
PMCPMC6515680
OpenAlexW2994283605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.